Imugene
Follow
Get notifications in MyBN when activity occurs.
Industry Lists
Public Companies - non WAImugene Limited (IMU) is an Australian immuno-oncology focused Biopharmaceutical Company developing HER2 + ve gastric and breast cancer vaccines. The Group's lead product is HER-Vaxx, a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu.
Contact Details
37 Bligh Street, Suite 1006, Level 10, SYDNEY NSW 2000
Lists and Charts
Share price
Closing price for the last 90 trading days
Powered by Morningstar ®
Total Shareholder Return as at 31/10/24
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| 838th | Imugene | 0% | 10% |
1740 WA (and selected non WA) listed companies ranked by
1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| th |  | Imugene | $5.0m |
1334 listed non wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Share Transactions
Total value as at the date of the transaction
Powered by Morningstar ®
Company Activity
| NEW ROLE: Paul Woodard, | 04 Oct 2024 |
| NEW ROLE: Bradley Glover, | 04 Oct 2024 |
| NEW ROLE: Kim Drapkin, Non-Executive Director | 31 Jul 2024 |
| NEWS: Tagged in Cancer-fighting mission shoots Imugene up ASX boards | 13 Nov 2023 |
| NEW ROLE: Jakob Dupoint, | 30 Oct 2023 |
| NEW ROLE: Giovanni Selvaggi, | 30 Oct 2023 |
| NEWS: Tagged in Healthtech banks on rising numbers | 07 Nov 2022 |
| NEW ROLE: Monil Shah, | 23 Sep 2022 |
| NEWS: Tagged in Where markets meet medicine; a biotech entrepreneur at the tip of the spear | 14 Feb 2022 |
